切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2022, Vol. 16 ›› Issue (06) : 614 -617. doi: 10.3877/cma.j.issn.1674-3946.2022.06.009

论著

同期肝切除联合脾切除在肝癌合并门静脉高压患者中的应用探讨
曹李1, 牛晓峰1, 孟令展1, 李虎1, 于雁宾1, 俞鹏1, 严锦1, 朱震宇1,()   
  1. 1. 100039 北京,解放军总医院第五医学中心肝病学部肝病外科
  • 收稿日期:2022-08-19 出版日期:2022-12-26
  • 通信作者: 朱震宇

Application of simultaneous hepatectomy combined with splenectomy in hepatocellular carcinoma patients with portal hypertension

Li Cao1, Xiaofeng Niu1, Lingzhan Meng1, Hu Li1, Yanbin Yu1, Peng Yu1, Jin Yan1, Zhenyu Zhu1,()   

  1. 1. Department of Hepatology Surgery,Department of Liver Medicine,Fifth Medical Center,General Hospital of PLA,Beijing 100039,China
  • Received:2022-08-19 Published:2022-12-26
  • Corresponding author: Zhenyu Zhu
  • Supported by:
    National Natural Science Foundation of China(92159305)
引用本文:

曹李, 牛晓峰, 孟令展, 李虎, 于雁宾, 俞鹏, 严锦, 朱震宇. 同期肝切除联合脾切除在肝癌合并门静脉高压患者中的应用探讨[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 614-617.

Li Cao, Xiaofeng Niu, Lingzhan Meng, Hu Li, Yanbin Yu, Peng Yu, Jin Yan, Zhenyu Zhu. Application of simultaneous hepatectomy combined with splenectomy in hepatocellular carcinoma patients with portal hypertension[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2022, 16(06): 614-617.

目的

探讨肝癌合并门静脉高压伴食管静脉曲张破裂出血的患者同期行肝癌切除和脾切除的安全性及可行性。

方法

回顾性分析2002年1月至2018年1月期间42例肝癌合并门静脉高压伴食管静脉曲张破裂出血行肝脾联合切除患者的临床资料。记录手术时间、术中出血量及术后并发症发生例数。采用门诊复查或电话随访方式随访,随访截至时间为2022年1月。

结果

开腹联合切除33例(78.6%),腹腔镜联合切除9例(21.4%)。其中8例行同期肝切除合并脾切除(19.0%),34例行同期肝切除合并脾切除同时加做贲门周围血管离断(81.0%)。术中出血量(771.4±500.2)ml,术中均未行肝门阻断;手术时间(5.6±2.6)h;42例患者术后病理学检查均证实为肝细胞癌。术后无围手术期临床死亡病例;术后3~6 d均恢复正常饮食。术后发生门脉系统血栓形成最为常见,共计出现32例(76.2%),单侧或者双侧胸腔积液21例(50.0%),肝周或者脾窝脓肿形成3例(7.1%),胆瘘2例(4.8%),严重门脉及脾静脉血栓形成致持续高胆红素血症1例(2.4%),后介入行肠系膜上动脉置管行肝素钠及尿激酶溶栓后好转。术后随访<5个月的3例(7.1%),超过1年的患者39例(92.9%),超过5年的患者9例(21.0%)。其中17例肿瘤复发或转移,并行进一步治疗(40.5%);13例复查胃镜出现不同程度食管静脉曲张(31.0%)。

结论

对于肝癌合并门静脉高压伴脾功能亢进及食管静脉曲张破裂出血的患者,可选择行肝脾联合切除,具有一定的安全性和可行性。

Objective

To investigate the safety and feasibility of hepatectomy and splenectomy in patients with hepatocellular carcinoma complicated with portal hypertension and esophageal varices rupture and hemorrhage.

Methods

From January 2002 to January 2018,the clinical data of 42 patients with hepatocellular carcinoma complicated with portal hypertension and esophageal varices rupture and hemorrhage who underwent hepatosplenectomy were retrospectively analyzed. The operation time,intraoperative blood loss and postoperative complications were recorded. The patients were followed up by outpatient review or telephone follow-up until January 2022.

Results

33 cases(78.6%)underwent laparotomy and 9 cases(21.4%)underwent laparoscopy. Among them,8 patients underwent simultaneous hepatectomy combined with splenectomy(19.0%),and 34 patients underwent simultaneous hepatectomy combined with splenectomy combined with pericardial devascularization(81.0%). The intraoperative blood loss was(771.4±500.2)ml. No hilar block was performed during the operation. The operation time was(5.6±2.6)hours. All 42 patients were confirmed to be hepatocellular carcinoma by postoperative pathological examination. There was no perioperative clinical death. All patients returned to normal diet 3 to 6 days after operation. Postoperative portal vein thrombosis was the most common occurrence,including 32 cases(76.2%),21 cases(50.0%)of unilateral or bilateral pleural effusion,3 cases(7.1%)of perihepatic or splenic fossa abscess,2 cases(4.8%)of bile leakage,1 case(2.4%)of persistent hyperbilirubinemia caused by severe portal vein and splenic vein thrombosis. After intervention,superior mesenteric artery catheterization and thrombolysis with heparin sodium and urokinase improved. Three patients(7.1%)were followed up for less than 5 months,39 patients(92.9%)were followed up for more than 1 year,and 9 patients(21.0%)were followed up for more than 5 years. Among them,17 cases had tumor recurrence or metastasis and received further treatment(40.5%). 13 cases(31.0%)had esophageal varices of varying degrees.

Conclusion

For patients with hepatocellular carcinoma complicated with portal hypertension,hypersplenism and esophageal varices rupture and bleeding,combined hepatosplenectomy can be selected,which has certain safety and feasibility.

表1 42例肝癌合并门静脉高压同期行脾切除联合肝切除患者基本情况
表2 42例肝癌合并门静脉高压同期行脾切除联合肝切除患者手术方式及术后并发症情况
[1]
Rich NEJohn BVParik ND,et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi‐center cohort of patients with cirrhosis[J]. Hepatology202072(5):1654-1665.
[2]
中国医师协会器官移植医师分会,中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志201935(2):275-280.
[3]
齐瑞兆,史宪杰,李志伟,等. 门静脉高压症上消化道出血不同指南诊治共识外科部分的比较分析[J]. 临床外科杂志201927(1):62-66.
[4]
何伟,李斌奎,元云飞. 肝细胞癌合并门静脉高压症治疗的争议[J/CD]. 中华肝脏外科手术学电子杂志20198(2):87-90.
[5]
乌吉斯古楞. 脾切除贲门周围血管离断术在老年原发性肝癌相关门静脉高压主治疗中的应用[J/CD]. 中华普外科手术学杂志(电子版)201913(1):73-76.
[6]
中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志201939(12):1241-1247.
[7]
党晓卫,张中杰,李路豪. 门静脉高压症性脾功能亢进的处理方式选择[J/CD]. 中华肝脏外科手术学电子杂志20198(3):276-278.
[8]
齐瑞兆,赵新,王胜智,等. 1118例开腹脾切除断流术治疗门静脉高压症术后并发症及生存分析[J]. 中华外科杂志201856(6):436-441.
[9]
Kong JShen SWang W. Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension:A systematic review and meta-analysis[J]. J Surg Oncol2019119(7):964-973.
[10]
付雍,杨广顺. 肝癌合并门静脉高压症的外科治疗[J]. 外科理论与实践201621(5):378-381.
[11]
徐锋,戴朝六,薛建,等. 肝癌切除联合脾切除治疗肝细胞癌合并脾功能亢进的体会[J]. 中国普外基础与临床杂志201421(4):473-475.
[12]
Xie XLLiu XOu J. Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?[J]. J Surg Oncol2019120(2):964-973.
[13]
Pei YChai SZhang Y,et al. Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension:a Retrospective Study[J]. J Gastrointest Surg201923(11):2151-2162.
[14]
Zhang QLi QShang F,et al. The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension[J]. Cancers(Basel)202214(13):3155.
[15]
贾守洪,鲁旭,彭彬. 多措施联合的腹腔镜肝切除术治疗肝癌合并肝硬化并门静脉高压症的临床应用研究[J/CD]. 中华普外科手术学杂志(电子版)202014(6):569-572.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 939-944.
[2] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[5] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[6] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[7] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[8] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[9] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[10] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[11] 马俊永, 王毅州, 李锡锋, 吴雅丽, 张小峰. 浅谈腹腔镜肝切除术出血防控策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 495-498.
[12] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[13] 李双喜, 胡宗凯, 赵静, 黄洁. 肝血管瘤治疗指征及治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 504-510.
[14] 王峰杰, 王礼光, 廖珊, 刘颖, 符荣党, 陈焕伟. 腹腔镜右半肝切除术治疗肝癌的安全性与疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 517-522.
[15] 张海涛, 贾哲, 马超, 张其坤, 武聚山, 郭庆良, 曾道炳, 栗光明, 王孟龙. 手术切除与射频消融治疗血管周围型单发小肝癌临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 523-527.
阅读次数
全文


摘要